The VITAL protocol: Expert opinion on a validated iron treatment algorithm for low hemoglobin in cancer patients in India.

Authors

Govind Babu, Jyoti Wadhwa, Joydeep Ghosh, Akanksha Chhabra, Akash Shah, Ashutosh Jain, Rushit Shah, Ghanashyam Biswas, Shruti Kate, Samit Purohit, Satvik Khaddar, Tushar Patil, Rakesh Kumar Mishra, G Vamshi Krishna Reddy, Darshit Shah, Ganapathi M Bhat, Suhas Vilasrao Agre, Shivam Singla

Published in

Journal of cancer research and therapeutics. Volume 22. Issue 5. Pages 795-803. Jul 01, 2026. Epub Oct 29, 2026.

Abstract

Anemia is a prevalent and clinically significant complication in patients with cancer, often exacerbated by chemotherapy. Iron correction remains an important component of treatment. Iron-deficiency anemia (IDA) is generally challenging to manage using oral formulations due to limited absorption, poor tolerability, and the need for rapid correction. Ferric carboxymaltose (FCM), a dextran-free preparation that delivers up to 1000 mg of iron in ≤15 minutes, was developed to address these challenges, making it a suitable treatment option for patients with IDA who cannot tolerate or do not respond to oral iron therapy. However, its real-world use in Indian oncology practice remains limited. To address this gap, an expert advisory board was convened to discuss the role of intravenous FCM 1000 mg in managing IDA among patients with cancer in India. The experts highlighted the significant burden of IDA in both hematologic and solid tumors, particularly gastrointestinal cancers, and emphasized the importance of iron profiling for accurate diagnosis. FCM 1000 mg was identified as the preferred treatment over oral iron in chemotherapy settings and was recommended as first-line therapy across the cancer care continuum due to its clinical efficacy, tolerability, patient quality of life benefits, cost-effectiveness, and ability to support uninterrupted chemotherapy. These expert insights are expected to provide a practical framework for Indian oncologists to improve IDA diagnosis and management, ultimately improving clinical outcomes and patient well-being.

PMID:
42955958
Bibliographic data and abstract were imported from PubMed on 30 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.